These results demonstrate that during treatment R patients are characterized by a significant reduction of circulating levels of ARG1 and that LOX-1+PMN-MDSCs may impact the response to pembrolizumab treatment, highlighting their potential role in the clinical outcome of (R/M) HNSCC patients also during immunotherapy. This evidence concerns the gene OLR1 and head and neck squamous cell carcinoma.